June 18, 2020 / 12:18 PM / 19 days ago

BRIEF-Eli Lilly Begins Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients

June 18 (Reuters) - Eli Lilly and Co:

* LILLY BEGINS A PHASE 3 CLINICAL TRIAL WITH BARICITINIB FOR HOSPITALIZED COVID-19 PATIENTS

* ELI LILLY AND CO - FIRST PATIENT ENROLLED IN PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY OF BARICITINIB

* ELI LILLY - EXPECTS TO ENROLL 400 PATIENTS IN PHASE 3 BARICITINIB TRIAL WITH DATA EXPECTED IN NEXT FEW MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below